on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Maintains Course in First Half of 2026
Eckert & Ziegler SE reported sales of €149.3 million in the first half of 2026, marking a slight increase compared to the previous year. Despite an adjusted EBIT decline of nearly 6% to €33.3 million, net income saw a 5% rise, reaching €22.4 million. These figures translate to earnings per share of €0.36.
The Medical segment experienced a 7% EBIT growth, signaling robust performance, with sales rising to €80.9 million. Radioisotopes continue to drive substantial revenue. The Isotope Products segment maintained steady sales at €68.5 million. Adjusted group sales were up by 4% and earnings increased by 9%, factoring out last year's extraordinary licensing revenue.
The Executive Board has reaffirmed the company's 2026 forecast, anticipating sales of about €320 million and EBIT around €80 million.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news